Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study)

南非艾滋病毒和结核病治疗的免疫介导药物不良反应:预测、预防和改善长期结果(IMARI SA 研究)

基本信息

  • 批准号:
    10382256
  • 负责人:
  • 金额:
    $ 33.01万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-04-21 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Immune-mediated adverse drug reactions (IM-ADRs) are a major obstacle to the successful treatment of both HIV and tuberculosis (TB) internationally. Their contribution to management complexity and economic burden is a particular problem in South Africa (SA) where 1 in 4 individuals in the population is HIV-infected and 1 in 5 patients with HIV develops a cutaneous adverse drug reaction during treatment. Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) are severe IM-ADRs that have mortalities that can exceed 40% and lead to prolonged hospitalization, higher healthcare costs and significantly constricted treatment options. The specific effect that these IM-ADRs have on HIV treatment outcomes has not been adequately measured. In addition, the IM-ADRs themselves are known to be associated with significant long-term disability and physical and mental health complications that have not been measured in HIV and HIV/TB co-infected populations. Preventive efforts for severe IM-ADRs such as DRESS and SJS/TEN have been fueled by promising discoveries such as the strong association between the HLA class I allele HLA-B*15:02 and carbamazepine SJS/TEN which has led to pre-treatment screening for HLA- B*15:02 before carbamazepine prescription in some Southeast Asian countries. Members of our group were responsible for the translation of HLA-B*57:01 screening to prevent abacavir hypersensitivity and we recently described a strong association between HLA-C*04:01 and nevirapine SJS/TEN in SA suggesting that HLA class I associations are also important for drugs used in the treatment and prevention of HIV. However, the genetic risk factors for IM-ADRs in African HIV-infected populations are incompletely understood and there are significant gaps in understanding the risk factors for IM-ADRs in drug commonly used in African HIV-TB co-infected populations. In SA and other resource poor African settings, given the high burden of HIV and TB, there is an urgent need to identify management strategies for IM-ADRs that will help improve prevention efforts, earlier diagnosis and treatment protocols. Our hypothesis tested will be that we will identify HLA and other genetic associations between SJS/TEN as well as DRESS and drugs used to prevent, treat and manage HIV and its co- morbidities. In specific aim 1 we will create a biorepository of DNA and other samples from IM-ADR cases related to drugs used to treat HIV and TB that includes underserviced areas in South Africa. Existing and new IM-ADR cases will undergo specific phenotype validation and causality adjudication. In specific aim 2 we will define HLA and other genetic risk factors associated with IM-ADRs in HIV/TB endemic settings. In specific aim 3 we will determine short and long-term complications and outcomes amongst a cohort of patients who have experienced IM-ADR and the specific impacts on HIV care. Using the synergistic gain of an existing US-South African collaboration we predict that our discoveries will create a roadmap for the prevention and management of IM-ADRs in complex HIV populations in resource poor settings internationally.
项目摘要 免疫介导的药物不良反应(IM-ADR)是成功治疗这两种疾病的主要障碍 艾滋病毒和结核病(TB)在国际上。它们对管理复杂性和经济负担的贡献是 南非(SA)的一个特殊问题是,人口中有四分之一的人感染艾滋病毒,五分之一的人感染艾滋病毒。 HIV患者在治疗过程中出现皮肤药物不良反应。stevens-johnson综合征 和中毒性表皮坏死松解症(SJS/TEN)和药物反应伴嗜酸性粒细胞增多和全身症状(DRESS) 是死亡率超过40%并导致住院时间延长的严重IM-ADR, 医疗保健成本和显著受限的治疗选择。这些IM-ADR对以下方面的具体影响 艾滋病毒治疗的成果尚未得到充分衡量。此外,IM-ADR本身是已知的 与严重的长期残疾和身心健康并发症有关, 在艾滋病毒和艾滋病毒/结核病合并感染人群中进行了测量。严重IM-ADR的预防措施,例如 DRESS和SJS/TEN受到了有希望的发现的推动,例如, HLA I类等位基因HLA-B * 15:02和卡马西平SJS/TEN,这导致了治疗前的HLA- B * 15:02在一些东南亚国家的卡马西平处方前。我们小组的成员是 负责翻译HLA-B * 57:01筛查,以防止阿巴卡韦过敏,我们最近 描述了HLA-C * 04:01和奈韦拉平SJS/TEN在SA中的强相关性,表明HLA类 I关联对于用于治疗和预防艾滋病毒的药物也很重要。然而,基因 非洲艾滋病毒感染人群中IM-ADR的风险因素尚未完全了解, 在了解非洲艾滋病毒/结核合并感染者常用药物中IM-ADR风险因素方面存在差距 人口。在南非和其他资源贫乏的非洲环境中,鉴于艾滋病毒和结核病的高负担, 迫切需要确定有助于改善预防工作的IM-ADR管理战略, 诊断和治疗方案。我们的假设是,我们将确定HLA和其他遗传 SJS/TEN以及DRESS与用于预防、治疗和管理艾滋病毒的药物之间的关联及其共同作用, 病态在具体目标1中,我们将创建一个DNA和其他IM-ADR病例样本的生物储存库 与用于治疗艾滋病毒和结核病的药物有关的药物,包括南非服务不足的地区。现有和 新的IM-ADR病例将接受特定表型验证和因果关系裁定。在具体目标2中, 将定义HLA和其他遗传风险因素与IM-ADR在艾滋病毒/结核病流行的设置。在 具体目标3,我们将确定短期和长期并发症和结果之间的队列, 经历过IM-ADR的患者以及对HIV护理的具体影响。使用的协同增益 根据现有的美国和南非合作,我们预测我们的发现将为非洲的发展创造一个路线图。 预防和管理国际资源匮乏环境中复杂艾滋病毒人群的IM-ADR。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Graeme Ayton Meintjes其他文献

Graeme Ayton Meintjes的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Graeme Ayton Meintjes', 18)}}的其他基金

HIV-associated Tuberculosis Training Program (HATTP)
HIV 相关结核病培训计划 (HATTP)
  • 批准号:
    10472830
  • 财政年份:
    2017
  • 资助金额:
    $ 33.01万
  • 项目类别:
HIV-associated Tuberculosis Training Program (HATTP)
HIV 相关结核病培训计划 (HATTP)
  • 批准号:
    9337925
  • 财政年份:
    2017
  • 资助金额:
    $ 33.01万
  • 项目类别:
HIV-associated Tuberculosis Training Program (HATTP)
HIV 相关结核病培训计划 (HATTP)
  • 批准号:
    10595639
  • 财政年份:
    2017
  • 资助金额:
    $ 33.01万
  • 项目类别:
HIV-associated Tuberculosis Training Program (HATTP)
HIV 相关结核病培训计划 (HATTP)
  • 批准号:
    10252833
  • 财政年份:
    2017
  • 资助金额:
    $ 33.01万
  • 项目类别:
HIV associated tuberculosis training program
HIV相关结核病培训计划
  • 批准号:
    8708239
  • 财政年份:
    2014
  • 资助金额:
    $ 33.01万
  • 项目类别:
HIV associated tuberculosis training program
HIV相关结核病培训计划
  • 批准号:
    8847990
  • 财政年份:
    2014
  • 资助金额:
    $ 33.01万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.01万
  • 项目类别:
    Research Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 33.01万
  • 项目类别:
    Standard Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 33.01万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 33.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 33.01万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 33.01万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 33.01万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 33.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 33.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 33.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了